Yonemori Kan, Tsuta Koji, Shimizu Chikako, Hatanaka Yutaka, Hashizume Kaoru, Ono Makiko, Nakanishi Yukihiro, Hasegawa Tadashi, Miyakita Yasuji, Narita Yoshitaka, Shibui Soichiro, Fujiwara Yasuhiro
Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
J Neurooncol. 2008 Nov;90(2):223-8. doi: 10.1007/s11060-008-9654-x. Epub 2008 Jul 23.
The aim of present study is to explore the immunohistochemical profiles of brain metastases from breast cancer. We retrospectively performed immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor type 2 (HER2/neu), and cytokeratin (CK) 5/6 in 29 patients with resected tumor specimens of brain metastases. Immunohistochemical staining for ER, PgR and HER2/neu was performed in 24 patients with primary tumors. The positive frequency of immunohistochemical profiles of ER, PgR, HER2/neu, and CK5/6, in the brain metastases were 13.8%, 6.9%, 37.9%, and 24.1%, respectively. The immunohistochemical profiles including ER, PgR, and HER2/neu of the primary tumor and the brain metastasis differed in seven patients (29.2%, N = 7/24). Interestingly, the biological characteristics of brain metastasis sometimes changed which were represented by immunohistochemical staining. Therefore, the changes in the biological features of breast cancer should be taken into account when developing treatment strategies, including new molecular-targeted drugs, for brain metastases.
本研究的目的是探讨乳腺癌脑转移瘤的免疫组化特征。我们回顾性地对29例有脑转移瘤切除肿瘤标本的患者进行了雌激素受体（ER）、孕激素受体（PgR）、人表皮生长因子受体2（HER2/neu）和细胞角蛋白（CK）5/6的免疫组化染色。对24例原发性肿瘤患者进行了ER、PgR和HER2/neu的免疫组化染色。脑转移瘤中ER、PgR、HER2/neu和CK5/6免疫组化特征的阳性频率分别为13.8%、6.9%、37.9%和24.1%。24例患者中，7例（29.2%，N = 7/24）原发性肿瘤和脑转移瘤的ER、PgR和HER2/neu免疫组化特征不同。有趣的是，脑转移瘤的生物学特征有时会发生变化，这通过免疫组化染色表现出来。因此，在制定包括新的分子靶向药物在内的脑转移瘤治疗策略时，应考虑乳腺癌生物学特征的变化。
